Literature DB >> 10763673

Adoption of perinatal group B streptococcal disease prevention recommendations by prenatal-care providers--Connecticut and Minnesota, 1998.

.   

Abstract

Group B streptococcal (GBS) infections are the leading bacterial cause of serious neonatal disease in the United States (1). In 1996, in collaboration with the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists, CDC issued consensus guidelines for preventing perinatal GBS disease (2-4). These guidelines recommend using either a screening-based or a risk-based strategy to identify women who should receive intrapartum antimicrobial prophylaxis. To assess adoption of the GBS disease prevention guidelines, the Connecticut and Minnesota state health departments surveyed prenatal-care providers during January-April 1998. This report presents the survey findings, which indicate that most prenatal-care providers in Connecticut and Minnesota have adopted perinatal GBS disease prevention policies and that strategy choice may vary by state and provider type.

Entities:  

Mesh:

Year:  2000        PMID: 10763673

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  3 in total

1.  Assessment of intrapartum antibiotic prophylaxis for the prevention of early-onset group B Streptococcal disease.

Authors:  Feng-Ying C Lin; Leonard E Weisman; Parvin Azimi; Amy E Young; Kathleen Chang; Mikhaela Cielo; Patricia Moyer; James F Troendle; Rachel Schneerson; John B Robbins
Journal:  Pediatr Infect Dis J       Date:  2011-09       Impact factor: 2.129

2.  Integrated monitoring of a new group B streptococcal disease prevention program and other perinatal infections.

Authors:  Anne Schuchat; Aaron Roome; Elizabeth R Zell; Heather Linardos; Sara Zywicki; Katherine L O'Brien
Journal:  Matern Child Health J       Date:  2002-06

3.  Perinatal group B streptococcal disease prevention, Minnesota.

Authors:  Craig A Morin; Karen White; Anne Schuchat; Richard N Danila; Ruth Lynfield
Journal:  Emerg Infect Dis       Date:  2005-09       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.